Slideshow
Author(s):
Here is evidence that metformin, especially at high doses and for long periods, is associated with increased risk for neurodegenerative diseases and dementia.
Insights From the TRAILBLAZER-ALZ Program: Elevated ARIA Risk with Donanemab Highlights the Need for Vigilant Monitoring
Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
Blueprints for Better Care: 2024 Neurology Guideline Highlights
Neurology Unwrapped: 2024’s Most Intriguing Conversations
PAP Treatment May Improve Parkinson-Related Cognitive Function
FDA Action Update, February 2025: Approvals, Designations, and Acceptances